Bookmark
Forward
QuickView for Reteplase (compound)
PubChem Substance
| Name: | reteplase |
|---|---|
| PubChem Substance ID: | 3813148 |
| Synonyms: |
133652-38-7; 173-527-Plasminogen activator (human tissue-type), 173-L-serine-174-L-tyrosine-175-L-glutamine-; Reteplase; Bm 06.022; Reteplase [USAN:INN]
|
DrugBank
Identification
| Name: | reteplase |
|---|---|
| Name (isomeric): | DB00015 |
| Drug Type: | biotech |
| Synonyms: |
tPA; t-plasminogen activator; Tissue-type plasminogen activator precursor; t- PA
|
| Brand: | Retavase (Roche), Retavase (Centocor) |
| Category: | Thrombolytic Agents |
| CAS number: | 133652-38-7 |
Pharmacology
| Indication: | For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction |
|---|---|
| Pharmacology: | Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction. |
| Mechanism of Action: | Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
